Drug Profile
Research programme: Rotavirus vaccines development - Medicago/Mitsubishi Tanabe Pharma
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Medicago
- Class Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Rotavirus infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Rotavirus-infections in Canada (Parenteral)
- 18 Sep 2013 Medicago has been acquired by Mitsubishi Tanabe Pharma Corporation
- 30 Jun 2013 Medicago produces plant-based rotavirus VLP vaccine candidate containing all four structural antigens of rotavirus